BCL2L2

Across TCGA pan-cancer cohorts, BCL2L2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BCL2L2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BCL2L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL2L2 expression acts as an unfavorable survival marker.

LSCC are the cancer types where BCL2L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.819	1.000	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

BCL2L2–LSCC (DFS)

Open the LSCC breakdown →